![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: CXorf21 |
Gene summary for CXORF21 |
![]() |
Gene information | Species | Human | Gene symbol | CXorf21 | Gene ID | 80231 |
Gene name | TLR adaptor interacting with endolysosomal SLC15A4 | |
Gene Alias | CXorf21 | |
Cytomap | Xp21.2 | |
Gene Type | protein-coding | GO ID | GO:0002221 | UniProtAcc | Q9HAI6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
80231 | CXorf21 | HCC1 | Human | Liver | HCC | 2.78e-04 | 8.55e-01 | 0.5336 |
80231 | CXorf21 | HCC2 | Human | Liver | HCC | 1.67e-09 | 8.83e-01 | 0.5341 |
80231 | CXorf21 | HCC5 | Human | Liver | HCC | 1.58e-04 | 4.27e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CXorf21 | SNV | Missense_Mutation | novel | c.794N>T | p.Ser265Leu | p.S265L | Q9HAI6 | protein_coding | deleterious(0.03) | benign(0.051) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
CXorf21 | SNV | Missense_Mutation | c.697G>T | p.Asp233Tyr | p.D233Y | Q9HAI6 | protein_coding | deleterious(0.05) | benign(0.277) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | c.457N>A | p.Gly153Ser | p.G153S | Q9HAI6 | protein_coding | deleterious(0.03) | probably_damaging(0.993) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
CXorf21 | SNV | Missense_Mutation | c.77N>C | p.Gln26Pro | p.Q26P | Q9HAI6 | protein_coding | tolerated(0.26) | benign(0.003) | TCGA-BH-A18K-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
CXorf21 | SNV | Missense_Mutation | novel | c.178N>C | p.Ser60Pro | p.S60P | Q9HAI6 | protein_coding | deleterious(0.03) | benign(0.003) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
CXorf21 | SNV | Missense_Mutation | c.617N>T | p.Ser206Phe | p.S206F | Q9HAI6 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-C5-A1BQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | CR | |
CXorf21 | SNV | Missense_Mutation | novel | c.327N>T | p.Glu109Asp | p.E109D | Q9HAI6 | protein_coding | tolerated(0.57) | benign(0.03) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | rs149817919 | c.821G>A | p.Arg274His | p.R274H | Q9HAI6 | protein_coding | tolerated(0.56) | benign(0.007) | TCGA-CK-5912-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CXorf21 | SNV | Missense_Mutation | c.256N>C | p.Thr86Pro | p.T86P | Q9HAI6 | protein_coding | tolerated(0.43) | benign(0.001) | TCGA-AG-3901-01 | Colorectum | rectum adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
CXorf21 | SNV | Missense_Mutation | c.406N>A | p.Ala136Thr | p.A136T | Q9HAI6 | protein_coding | tolerated(0.14) | probably_damaging(0.91) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |